
The EMA issued a positive opinion for a 3-month dapivirine vaginal ring for HIV prevention in women and girls aged 16 and older, cutting annual product costs by nearly 60%.
There were a number of FDA approvals in recent weeks. Here is a listing of the approvals including the news reports and review of the phase 3 study data.
This is our monthly column looking at federal regulatory topics including recent decisions, personnel changes, and news related to the agencies and infectious disease.





